SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is gaining momentum as investors rally behind its unique "brandcoin" model, which emphasizes consistent community-led initiatives and real-world product expansion. The community remains highly active, frequently highlighting their diverse ecosystemranging from beverages to athletic sponsorshipsas proof of the project's long-term utility and commitment to organic growth.

Travelzoo Inc. operates as a global media commerce company which engages in the provision of information to subscribers and website users about travel, entertainment, and local deals available from various companies. Its publications and products include the Travelzoo website (travelzoo.com), the Travelzoo iPhone and Android apps, the Travelzoo Top 20 e-mail newsletter, and the Newsflash e-mail alert service. The company operates through the following geographical segments: Asia Pacific, Europe, and North America. Travelzoo was founded by Ralph Bartel on May 21, 1998 and is headquartered in New York, NY.

Travelzoo

Travelzoo is seeing increased investor interest as the community highlights the aggressive pace of the company's million-share stock buyback program, which is significantly tightening the public float. Enthusiastic market participants are closely tracking these repurchases alongside consistent insider buying, betting that the reduced share count could act as a catalyst for a sustained upward move.

Provides investment banking, securities and asset management services

Goldman Sachs Group, Inc.

Goldman Sachs is trending as investors digest its latest earnings report, which showcased resilience in trading and banking fees despite market volatility, while the stock continues to be a focal point for institutional capital flow monitoring. Community sentiment remains split between long-term bullish holders focused on its leadership in mega-IPOs and short-term traders debating whether the stock is overextended at current levels.

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Carnival Corp (CCL) is trending as investors react to fluctuating oil prices and evolving geopolitical developments in the Middle East, which remain the primary drivers of volatility for cruise stocks. The community is actively debating the impact of these macro headwinds versus strong fundamental metrics like record bookings and recent share buyback programs, with many participants looking for a sustained breakout as the conflict landscape shifts.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is experiencing heightened investor interest and positive market sentiment following news of a significant premarket gain driven by promising late-stage trial results for a combination lung cancer therapy. The community is actively discussing the company's long-term pipeline potential in light of impending patent expirations for its blockbuster drug, Keytruda, while tracking competitive developments in oncology.

Harmonic, Inc. engages in the development and sale of video delivery software, products, system solutions, and services. It operates through the Video and Broadband segments. The Video segment sells video processing and production and playout services to cable operators, satellite and telecommunications pay-TV service providers, and broadcast and media companies. The Broadband segment offers solutions to cable operators broadband access solutions and related services, including cOS software-based broadband access solution, to broadband operators globally. The company was founded in June 1988 and is headquartered in San Jose, CA.

Harmonic, Inc.

Harmonic, Inc. is capturing significant investor attention as it transitions from hardware-focused operations to a pure-play broadband software model (cOS), which community members believe creates a superior, recurring revenue profile that is not yet fully reflected in its valuation. Discussions center on the stock’s potential for multiple expansion driven by high-beta momentum, institutional accumulation, and an ongoing shift in industry cost structures that creates strong switching costs for major cable and broadband operators.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing a surge in investor attention and sentiment following the announcement of a multi-million dollar government award and equity stake, which has officially validated its technology as a strategic national infrastructure asset. The community is actively discussing the company's competitive advantages in neutral-atom technology and sensing over sector peers, with many viewing the government backing as a catalyst for future institutional accumulation and long-term valuation growth.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

Canton Network is capturing investor attention due to its role as institutional-grade infrastructure for real-world asset tokenization, supported by high-profile partnerships with global financial giants. While some participants are optimistic about its utility and adoption, the community remains divided over ongoing token unlocks and concerns regarding supply inflation.

Pop Cat refers to a series of videos in which using an image of a cat named Oatmeal, the cat is photoshopped as if it's opening its mouth wide in an O shape.

Popcat

The Popcat community is actively debating the token's long-term potential as it navigates significant price volatility and consolidation. Discussions are split between investors viewing current dips as accumulation opportunities and skeptics concerned about momentum, while market participants watch its correlation with the broader Solana ecosystem and other cat-themed meme coins.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is experiencing heightened volatility and intense debate as investors weigh significant China-focused stimulus expectations against ongoing geopolitical tensions and regulatory shifts. While some in the community see the current valuations as a contrarian long-term accumulation opportunity, others remain skeptical due to persistent market underperformance and lingering concerns over foreign investment risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eyepoint Pharmaceuticals Q1 Earnings Call Highlights

EyePoint Pharmaceuticals (NASDAQ:EYPT) executives told investors the company is approaching what they described as a "pivotal inflection point" for its lead program, DURAVYU, with phase III wet age-related macular degeneration (wet AMD) top-line data expected beginning mid-year and a rapidly enrolli...

EyePoint (EYPT) Reports Q1 Loss, Tops Revenue Estimates

EyePoint (EYPT) delivered earnings and revenue surprises of -25.32% and +132.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Analysts

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been given a consensus rating of "Buy" by the eight research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have...

Eyepoint Pharmaceuticals (EYPT) to Release Quarterly Earnings on Wednesday

Eyepoint Pharmaceuticals (NASDAQ:EYPT) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Sells $36,555.00 in Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction on Friday, April 17th. The shares were sold...

Insider Selling: Eyepoint Pharmaceuticals (NASDAQ:EYPT) Insider Sells 2,437 Shares of Stock

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The sale was disclosed...

JPMorgan Chase & Co. Sells 217,150 Shares of Eyepoint Pharmaceuticals, Inc. $EYPT

JPMorgan Chase & Co. cut its stake in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 87.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,262 shares of the company's stock after selling 217,150 share...

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Buy" by Brokerages

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has earned a consensus recommendation of "Buy" from the eight brokerages that are currently covering the company, Marketbeat reports...

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 3.7% - Time to Sell?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 3.7% - Time to Sell...

Aberdeen Group plc Has $29.34 Million Position in Eyepoint Pharmaceuticals, Inc. $EYPT

Aberdeen Group plc boosted its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 101.6% in the 4th quarter, according to its most recent filing with the Securities and...

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.93	--	--	N/A
Q1 '26	-$0.81	-$0.99	-22.92%	MISSED
Q4 '25	-$0.75	-$0.81	-7.35%	MISSED
Q3 '25	-$0.77	-$0.85	-10.49%	MISSED
Q2 '25	-$0.82	-$0.85	-3.32%	MISSED

EYPT
EyePoint Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Compact View

Latest EYPT News

EYPTEyePoint Pharmaceuticals Inc